Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cryoport, Inc.CYRX · Entity 5125 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cryoport, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,052 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,350 · Balance 69,052 F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. |
| Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2033-06-05 | Direct | 16,077 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,077 · Balance 16,077 F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2019 Filed Oct 2, 2019 23:14 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 695 | $16.55 | $11,502.25 |
DisclosureSEC source: 0001144204-19-047047 · tv530455_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,098 Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 23:42 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 649 | $17.72 | $11,500.28 |
DisclosureSEC source: 0001144204-19-033665 · tv524716_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,403 Read SEC document |
| May 02, 2019 Filed May 3, 2019 23:58 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001144204-19-023719 · tv520665_4.xml · derivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-05-02 F1 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the next twelve (12) months beginning on 05/02/2019. Read SEC document |
| April 10, 2019 Filed Apr 10, 2019 19:28 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 754 | $13.27 | $10,005.58 |
DisclosureSEC source: 0001144204-19-019045 · tv518647_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 754 Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 23:53 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 12,850 | $9.73 Strike: $9.73 | $125,030.50 |
DisclosureSEC source: 0001144204-19-001136 · tv510467_form4.xml · derivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,850 Underlying: Common Stock · 12,850 shares Expires 2029-01-04 F2 · derivative.exercise_date: 2,850 of the options vest on January 17, 2019 and 1/4 of the remaining 10,000 options vest on the 17th of each month for four months beginning on 2/17/2019. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 23:53 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 50,000 | $9.73 Strike: $9.73 | $486,500.00 |
DisclosureSEC source: 0001144204-19-001136 · tv510467_form4.xml · derivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-04 F1 · derivative.exercise_date: 1/36 of the options vest on the 4th of each month for thirty six months beginning on 1/4/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.